You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

173 Results
Drug
Other Name(s): Lonsurf®
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Selinexor and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    selinexor - In combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Nov 2024
Drug
Other Name(s): Erwinase®
Jan 2020
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Sep 2020
Guidelines and Advice
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Aug 2020
Guidelines and Advice
Status: Current
ID: GL 8-10
Version: N/A
Feb 2020
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Curative, Palliative
Mar 2020
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Mar 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    dexamethasone
Mar 2020

Pages